Please select the option that best describes you:

Do you omit PMRT for patients who would have been eligible for NSABP B-51, but are found to have significant pure LVSI only, without stromal carcinoma, after neoadjuvant chemotherapy?  

Would the ER/HER2 receptor subtype affect your answer?



Answer from: Radiation Oncologist at Community Practice
Sign In or Register to read more